Coexisting diseases modifying each other’s presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism
Abstract
Introduction. Turner syndrome presents with one of the most frequent chromosomal aberrations in female, typically presented with growth retardation, ovarian insufficiency, facial dysmorphism, and numerous other somatic stigmata. Gigantism is an extremely rare condition resulting from an excessive growth hormone (GH) secretion that occurs during childhood before the fusion of epiphyseal growth plates. The major clinical feature of gigantism is growth acceleration, although these patients also suffer from hypogonadism and soft tissue hypertrophy. Case report. We presented a girl with mosaic Turner syndrome, delayed puberty and normal linear growth for the sex and age, due to the simultaneous GH hypersecretion by pituitary tumor. In the presented case all the typical phenotypic stigmata related to Turner syndrome were missing. Due to excessive pituitary GH secretion during the period while the epiphyseal growth plates of the long bones are still open, characteristic stagnation in longitudinal growth has not been demonstrated. The patient presented with delayed puberty and primary amenorrhea along with a sudden appearance of clinical signs of hypersomatotropinism, which were the reasons for seeking medical help at the age of 16. Conclusion. Physical examination of children presenting with delayed puberty but without growth arrest must include an overall hormonal and genetic testing even in the cases when typical clinical presentations of genetic disorder are absent. To the best of our knowledge, this is the first reported case of simultaneous presence of Turner syndrome and gigantism in the literature.
References
Bondy CA, Turner Syndrome Study Group. Care of girls and wom-en with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92(1): 10−25.
Gravholt CH. Epidemiological, endocrine and metabolic fea-tures in Turner syndrome. Eur J Endocrinol 2004; 151(6): 657−87.
Eugster E, Pescovitz O. Gigantism. J Clin Endocrinol Metab 1999; 84(12): 4379−84.
Bolanowski M, Lomna-Bogdanov E, Kosmala W, Malczewska J, Slezak R, Zadrozna B, et al. Turner's syndrome followed by acro-megaly in the third decade of life: an unusual coincidence of two rare conditions. Gynecol Endocrinol 2002; 16(4): 331−4.
Yamazaki M, Sato A, Nishio S, Takeda T, Miyamoto T, Katai M, et al. Acromegaly accompanied by Turner Syndrome with 47, XXX/45, X/46, XX mosaicism. Inter Med 2009; 48(6): 447−53.
Kido G, Miyagi A, Shibuya T, Miyagami M, Tsubokawa T, Sawada T. Turner's syndrome with pituitary hyperplasia: a case report. No Shinkei Geka 1994; 22(4): 333−8. (Japanese)
Mermiliod JA, Gatchair-Rose A, Svec F. Pituitary tumor and low gonadotropins in patients with Turner's syndrome. J La State Med Soc 1995; 147(12): 540−3.
Pejaver RK, Watson AH. Pituitary microadenoma in Turner's syndrome. Br J Clin Pract 1995; 49(4): 223−4.
Gaspar L, Julesz J, Kocsis J, Pasztor E, Laszlo F. Mosaic Turner's syndrome and pituitary microadenoma. Exp Clin Endocrinol 1985; 86(1): 87−92.
Dötsch J, Schoof E, Hensen J, Dörr HG. Prolactinoma causing secondary amenorrhoea in woman with Ullrich-Turner syn-drome. Horm Res 1999; 51(5): 256−7.
Lu PW, Silink M, Johnston I, Cowell CT, Jimenez M. Pituitary gi-gantism. Arch Dis Child 1992; 67(8): 1039−41.
Spiliotis B. Recombinant human growth hormone in the treat-ment of Turner syndrome. Ther Clin Risk Manag 2008; 4(6): 1177−83.
Kiess W, Kratzsch J, Pfaeffle R. The growth hormone (GH) and insulin-like growth factor (IGF) system in girls and women with Turner syndrome. In: Gravholt CH, Bondy CA, editors. International Congress Series 1298: Wellness for Girls and Woman with Turner Syndrome. Amsterdam: Elsevier; 2006. p. 63−70.
Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 2006; 65(4): 413−22.
Rosenfield RG, Hwa V. New molecular mechanism of GH resis-tance. Eur J Endocrinol 2004; 151(Suppl 1): S11−5.
Hochberg Z, Aviram M, Rubin D, Pollack S. Decreased sensitivity to insulin-like growth factor I in Turner's syndrome: a study of monocytes and T lymphocytes. Eur J Clin Invest 1997; 27(7): 543−7.
Barreca A, Larizza D, Damonte G, Arvigo M, Ponzani P, Cesarone, et al. Insulin-like growth factors (IGF-I i IGF-II) and IGF-binding protein-3 production by fibroblasts of patients with Turner's syndrome in culture. J Clin Endocrinol Metab 1997; 82(4): 1041−6.
Lebl J, Pruhova S, Zapletalova J, Pechova M. IGF–I resistance and Turner's syndrome. J Pediatr Endocrinol Metab 2001; 14(1): 37−41.
de Menis E, Gola M, Giustina A. Development of acromegaly in patient with anorexia nervosa: pathogenic and diagnostic im-plications. J Endocrinol Invest 2006; 29(9): 821−5.
Ezzat S. The role of hormones, growth factors and their re-ceptors in pituitary tumorogenesis. Brain Pathol 2001; 11(3): 356−70.
Romero CJ, Pine-Twaddell E, Sima DI, Miller RS, He L, Wondisford F, et al. Insulin like growth factor 1 mediates negative feedback to somatotroph GH expression via POU1F1/CREB binding protein interaction. Mol Cell Biol 2012; 32(21): 4258−69.
Melmed S. Mechanism for pituitary tumorogenesis: The plastic pituitary. J Clin Invest 2003; 112(11): 1603−18.
Scheithauer BW, Kovacs K, Horvath E, Young WE, Lloyd RV. The pituitary in Turner's syndrome. Endocr Pathol 2005; 16(3): 195−200.